Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Harrow Inc (NQ: HROW )

42.90 -0.98 (-2.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 330,682
Open 44.17
Bid (Size) 41.25 (1)
Ask (Size) 45.56 (1)
Prev. Close 43.88
Today's Range 42.73 - 44.45
52wk Range 8.720 - 59.23
Shares Outstanding 35,614,718
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
From Harrow, Inc.
Via Business Wire
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
From Melt Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+259.00%
+259.00%
1 Month
-20.88%
-20.88%
3 Month
+0.47%
+0.47%
6 Month
+139.80%
+139.80%
1 Year
+357.36%
+357.36%

More News

Read More
Harrow Announces Participation in Upcoming Investor Conferences
From Harrow, Inc.
Via Business Wire
Earnings Scheduled For November 13, 2024
Via Benzinga
Earnings Outlook For Harrow
Via Benzinga
The Analyst Landscape: 4 Takes On Harrow
Via Benzinga
Navigating 5 Analyst Ratings For Harrow
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Harrow Announces Third Quarter 2024 Financial Results
From Harrow, Inc.
Via Business Wire
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
From Harrow, Inc.
Via Business Wire
Harrow Announces Market Access Wins for VEVYE®
From Harrow, Inc.
Via Business Wire
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
From Harrow, Inc.
Via Business Wire
Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
From Harrow, Inc.
Via Business Wire
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
From Harrow, Inc.
Via Business Wire
Harrow Relaunches TRIESENCE®
From Harrow, Inc.
Via Business Wire
Harrow Announces Nashville Expansion
From Harrow, Inc.
Via Business Wire
Harrow to Present at Three Investor Conferences in September in New York
From Harrow, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
HROW Stock Earnings: Harrow Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Harrow Announces Second Quarter 2024 Financial Results
From Harrow, Inc.
Via Business Wire
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
From Harrow, Inc.
Via Business Wire
Harrow to Attend 2024 ASRS Annual Meeting
From Harrow, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.